CN112538506A - Process method for synthesizing chloramphenicol succinate through enzyme catalysis - Google Patents
Process method for synthesizing chloramphenicol succinate through enzyme catalysis Download PDFInfo
- Publication number
- CN112538506A CN112538506A CN202011577379.4A CN202011577379A CN112538506A CN 112538506 A CN112538506 A CN 112538506A CN 202011577379 A CN202011577379 A CN 202011577379A CN 112538506 A CN112538506 A CN 112538506A
- Authority
- CN
- China
- Prior art keywords
- chloramphenicol
- solvent
- lipase
- reaction
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 37
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 37
- LIRCDOVJWUGTMW-ZWNOBZJWSA-N Chloramphenicol succinate Chemical compound OC(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 LIRCDOVJWUGTMW-ZWNOBZJWSA-N 0.000 title claims abstract description 30
- 229960004357 chloramphenicol succinate Drugs 0.000 title claims abstract description 30
- 238000006555 catalytic reaction Methods 0.000 title claims abstract description 15
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 8
- 108090001060 Lipase Proteins 0.000 claims abstract description 41
- 102000004882 Lipase Human genes 0.000 claims abstract description 41
- 239000004367 Lipase Substances 0.000 claims abstract description 41
- 235000019421 lipase Nutrition 0.000 claims abstract description 41
- 102000004157 Hydrolases Human genes 0.000 claims abstract description 16
- 108090000604 Hydrolases Proteins 0.000 claims abstract description 16
- 102000057234 Acyl transferases Human genes 0.000 claims abstract description 4
- 108700016155 Acyl transferases Proteins 0.000 claims abstract description 4
- 108091005804 Peptidases Proteins 0.000 claims abstract description 4
- 239000004365 Protease Substances 0.000 claims abstract description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 58
- 239000002904 solvent Substances 0.000 claims description 55
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 41
- 229960005091 chloramphenicol Drugs 0.000 claims description 40
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 23
- 229940014800 succinic anhydride Drugs 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 239000012265 solid product Substances 0.000 claims description 14
- 241001661345 Moesziomyces antarcticus Species 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000007670 refining Methods 0.000 claims description 8
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002808 molecular sieve Substances 0.000 claims description 7
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical group [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 241000228245 Aspergillus niger Species 0.000 claims description 5
- 102100021851 Calbindin Human genes 0.000 claims description 5
- 101000898082 Homo sapiens Calbindin Proteins 0.000 claims description 5
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 5
- 101001021643 Pseudozyma antarctica Lipase B Proteins 0.000 claims description 5
- 240000005384 Rhizopus oryzae Species 0.000 claims description 5
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 101000968489 Rhizomucor miehei Lipase Proteins 0.000 claims description 3
- 238000004042 decolorization Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000003672 processing method Methods 0.000 claims 7
- 239000006096 absorbing agent Substances 0.000 claims 3
- 244000291564 Allium cepa Species 0.000 claims 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 239000005909 Kieselgur Substances 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000235402 Rhizomucor Species 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000000967 suction filtration Methods 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 241000235403 Rhizomucor miehei Species 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000589513 Burkholderia cepacia Species 0.000 description 4
- 241000222175 Diutina rugosa Species 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 108010048733 Lipozyme Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010084311 Novozyme 435 Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000223258 Thermomyces lanuginosus Species 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 108010031797 Candida antarctica lipase B Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000531819 Streptomyces venezuelae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- HXYXTCJDWHHCBW-UHFFFAOYSA-N acetonitrile;toluene Chemical compound CC#N.CC1=CC=CC=C1 HXYXTCJDWHHCBW-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- QNXIYXGRPXRGOB-UHFFFAOYSA-N oxolane;propan-2-one Chemical compound CC(C)=O.C1CCOC1 QNXIYXGRPXRGOB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940126572 wide-spectrum antibiotic Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to a process method for synthesizing chloramphenicol succinate through enzyme catalysis, which belongs to the technical field of biological medicine. The hydrolase is any one or combination of protease, lipase and acyltransferase, wherein the enzyme can be natural source or obtained by recombination through genetic engineering technology. Compared with the existing process, the enzyme catalysis process adopted by the invention is more convenient and safer, has less pollution, higher quality and lower cost, and is more suitable for large-scale industrial production of chloramphenicol succinate.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a synthesis method of chloramphenicol succinate.
Background
Chloramphenicol (Chloramphenicol) is an amidoalcohol wide spectrum antibiotic found in Streptomyces venezuelae. It has inhibitory effect on gram-positive and gram-negative bacteria, anaerobe, spirochete, chlamydia and rickettsia. The traditional Chinese medicine composition is mainly used for treating typhoid fever, influenza, pneumonia, meningitis and the like in clinic, and is also effective for pertussis, trachoma, bacillary dysentery, urinary tract infection and the like. The chloramphenicol antibiotic is still a first-line clinical medicine because of its large use, low price and easy large-scale synthesis and preparation.
However, chloramphenicol has serious adverse effects of inhibiting bone marrow hemopoiesis, and can reduce various blood cells of human body, even produce irreversible aplastic anemia, thereby limiting its expanded use. Therefore, people modify the structure of chloramphenicol, so as to reduce toxic and side effects while maintaining drug effects, wherein chloramphenicol succinate is a more successful chloramphenicol derivative.
Chloramphenicol Succinate (Chloramphenicol Succinate) is named as D-threo- (-) -N-alpha- (hydroxymethyl) -beta-hydroxy-p-nitrophenylethyl-2, 2-dichloroacetamide-alpha-Succinate (DSA), can be rapidly hydrolyzed in vivo to free Chloramphenicol for generating effect, has the same or better drug effect as Chloramphenicol, and has greatly reduced side effect compared with Chloramphenicol. The classical preparation method is prepared by reacting chloramphenicol and succinic anhydride under the catalysis of organic base, and related chemical synthesis methods in patents, papers and other documents are reported more, but the traditional chemical synthesis methods have the disadvantages of more raw material consumption, lower yield, high energy consumption in the reaction process, high toxicity of reaction reagents and environmental pollution, and the activity of the used traditional chemical catalyst is lower, so that the reaction selectivity is poor, more byproducts are generated, the yield is not high, the product quality is lower, and the post-treatment refining is difficult. These disadvantages limit the industrial application of the process.
In summary, there is a need to develop a method for preparing chloramphenicol succinate with lower cost, more convenient operation, more safety and higher efficiency.
Disclosure of Invention
Aiming at the problems, the invention aims to provide a process method for synthesizing chloramphenicol succinate by enzyme catalysis, which adopts hydrolase to catalyze chloramphenicol and succinic anhydride to carry out esterification reaction to generate chloramphenicol succinate, has higher production efficiency and product quality, and has the advantages of convenient operation, low cost, environmental friendliness, safety, high efficiency and the like.
In order to achieve the purpose, the invention adopts the specific scheme that:
a process method for synthesizing chloramphenicol succinate through enzyme catalysis comprises the following steps:
step one, reacting chloramphenicol and succinic anhydride under the catalysis of a biological enzyme to generate chloramphenicol succinate:
dissolving chloramphenicol and succinic anhydride in a solvent, adding hydrolase, controlling the temperature in a water bath at 0-60 ℃ for mixing reaction, and stopping the reaction when chloramphenicol conversion is completed; recovering enzyme catalyst, decolorizing the reaction solution with activated carbon, vacuum filtering, and distilling the filtrate under reduced pressure to remove solvent to obtain white solid product;
the molar ratio of the succinic anhydride to the chloramphenicol is 1-1.2: 1; the hydrolase is one or more of protease, lipase and acyltransferase, and the addition amount of the hydrolase is 5-50% of the mass of the chloramphenicol;
step two, refining:
adding a good solvent into the white solid product obtained in the step one, stirring at room temperature until the good solvent is dissolved, and then slowly adding a poor solvent; or, adding a crystallization solvent consisting of a good solvent and a poor solvent into the white solid product obtained in the step one; slowly cooling to 0-5 ℃, standing at constant temperature, separating out white needle crystals, filtering, and drying the obtained crystals for 2 hours in vacuum at 50 ℃ to obtain a refined product;
the good solvent is any one or more of methanol, ethanol or acetone; the poor solvent is water; the volume ratio of the good solvent to the poor solvent is 1:1, and the total adding amount of the good solvent and the poor solvent is 8-12 times of the mass of the white solid product.
In the first step, the solvent is any one or a mixture of more of acetone, acetonitrile, tetrahydrofuran, methyl tert-butyl ether, dioxane, toluene and isopropyl ether, and acetone is preferred.
In the first step, the lipase is one or more of thermophilic fungi, rhizopus oryzae, candida antarctica, candida rugosa, pseudomonas cepacia, pseudomonas fluorescens, aspergillus niger, bacillus subtilis and rhizopus oryzae. More preferably, the lipase is candida antarctica lipase CALB or rhizomucor miehei lipase RML. Most preferably, the lipase is candida antarctica lipase CALB.
In the first step, the hydrolase is an immobilized enzyme.
In the first step, the adding amount of the hydrolase is 10-20% of the mass of the chloramphenicol.
In the first step, the temperature of the water bath is controlled to be 40 ℃ to carry out mixing reaction.
In the first step, the mixing reaction is carried out in a kettle type stirring reactor, an enzyme filled fixed bed reactor or a shaking table.
In the first step, a water absorbent is added to the reaction system before the mixing reaction. Preferably, the water absorbent is molecular sieve, silica gel, diatomite or anhydrous sodium sulfate, and the adding amount of the water absorbent is 5% of the mass of the solvent.
In the second step, the refining process comprises the following specific steps: under the condition of 20-40 ℃, firstly adding methanol, stirring and dissolving a white solid product crude product of chloramphenicol succinate, then slowly adding purified water, slowly cooling to 0-5 ℃, and finally standing for 2-6 hours for crystallization.
Has the advantages that:
compared with the prior art, the method has the advantages of higher production efficiency and product quality, convenient operation, low cost, environmental friendliness, safety, high efficiency and the like, and is more suitable for industrial production of chloramphenicol succinate.
Drawings
FIG. 1 is a reaction equation for the reaction described in example 1;
FIG. 2 is the reaction equation for the reaction described in example 2;
FIG. 3 is the reaction equation for the reaction described in example 3;
FIG. 4 is the reaction equation for the reaction described in example 4;
FIG. 5 is the reaction equation for the reaction described in example 5;
FIG. 6 is a chromatogram of chloramphenicol succinate prepared by the present invention.
Detailed Description
A process method for synthesizing chloramphenicol succinate through enzyme catalysis comprises the following steps:
step one, reacting chloramphenicol and succinic anhydride under the catalysis of a biological enzyme to generate chloramphenicol succinate:
dissolving chloramphenicol and succinic anhydride in a certain proportion in a solvent, adding hydrolase, performing water bath temperature control mixing reaction, and stopping the reaction when chloramphenicol conversion is completed; recovering enzyme catalyst, decolorizing the reaction solution with activated carbon, vacuum filtering, and distilling the filtrate under reduced pressure to remove solvent to obtain white solid product;
step two, refining:
and (3) adding a good solvent into the white solid product obtained in the step one, stirring at room temperature until the good solvent is dissolved, then slowly adding a poor solvent until the product is saturated, slowly cooling to 4 ℃, standing at constant temperature, separating out white needle crystals, filtering, and drying the obtained crystals for 2 hours in vacuum at 50 ℃ to obtain a refined product.
In the first step, the hydrolase is one or more of protease, lipase and acyltransferase.
Further, the lipase is derived from any one or more of thermophilic fungi (Thermomyces lanuginosa), Rhizomucor miehei (Rhizomucor miehei), Candida Antarctica (Candida Antarctica), Candida rugosa (Candida rugosa), Pseudomonas cepacia (Pseudomonas cepacia), Pseudomonas fluorescens (Pseudomonas fluorescens), Aspergillus niger (Aspergillus niger), Bacillus subtilis (Bacillus subtilis), and Rhizopus oryzae (Rhizopus oryzae). More preferably, the lipases used are candida antarctica lipase CALB and rhizomucor miehei lipase RML. Most preferably, the lipase used is candida antarctica lipase CALB.
The hydrolase used according to the invention is not limited to natural sources, but also includes enzymes which are recombined by molecular microbiology. The form of the enzyme to be used is not limited, and may be either dry powder or immobilized, and since the immobilized enzyme is used, the subsequent treatment is easy and the enzyme can be recovered and reused, the hydrolase is particularly preferably an immobilized enzyme. Among the above numerous lipases, we found that lipases derived from Candida Antarctica and Rhizomucor miehei have better activity for the selective esterification of chloramphenicol and succinic anhydride. Immobilized enzymes are generally used to make the enzymes more stable, convenient and reusable for post-treatment, and for example, Candida antarctica lipase B (Novozym 435) immobilized with macroporous adsorption resin and Mucor miehei lipase (Lipozyme RM IM) immobilized with ion exchange resin may be selected.
In the first step, the solvent is any one of acetone, acetonitrile, tetrahydrofuran, methyl tert-butyl ether, dioxane, toluene and isopropyl ether or a mixture thereof. In many cases, acetone is used as the solvent, so that the catalytic activity is higher, the conversion rate is more complete, the boiling point is lower, and the distillation recovery is easy, so that acetone is selected as the solvent, but the acetone is not limited.
In the first step, the molar ratio of the added raw material succinic anhydride to chloramphenicol can be 1-1.2, the enzymatic reaction has high activity and high selectivity and few side reactions, the succinic anhydride and chloramphenicol can completely react according to the molar ratio of 1:1 in a theoretical amount, and the raw material succinic anhydride with lower price is slightly excessive in the actual process, wherein the preferred molar ratio is 1.1.
In the first step, the mass ratio of the added lipase to the chloramphenicol is 5-50% by taking the specific enzyme activity of the immobilized lipase as a standard of 10000U/g, and if the recycling of the enzyme is not considered, the mass ratio is more preferably 10-20%, and the most preferably 15%. The immobilized lipase catalytic reaction is carried out at 0-60 ℃, the enzyme is more stable and less prone to inactivation at a lower temperature, but the catalytic activity is lower and the reaction is slower; at higher temperature, the enzyme activity is higher, the reaction is fast, but the enzyme is unstable and is easy to inactivate. The reaction temperature is preferably 40 ℃ in consideration of the stability, catalytic activity and energy consumption of the lipase, and the esterification reaction between the succinic anhydride and the chloramphenicol can be completely converted within 8 hours under the condition of ensuring that the addition amount of the immobilized lipase is 15 percent.
The invention relates to an esterification reaction process between chloramphenicol and succinic anhydride catalyzed by lipase, the lipase is one of hydrolytic enzymes and can catalyze ester hydrolysis, so the system is required to be ensured to be anhydrous. In the process step (1), molecular sieves, silica gel, diatomite, anhydrous sodium sulfate and other water absorbents can be used for removing a small amount of water brought by a solvent, so that the hydrolysis reverse reaction is reduced to the maximum extent, the esterification reaction is promoted, and the reaction conversion rate is improved.
In process step (1) according to the invention, the decolorization process by activated carbon is known to the person skilled in the art. Specifically, the activated carbon can be powder, 5% of the mass of the chloramphenicol raw material is added, and the mixture is heated to boil and stirred for 10 minutes.
According to the present invention, in the process step (1), the enzyme-catalyzed reaction process generally employs a tank-type stirred reactor, and the reaction may be carried out by shaking in a shaker, considering that the shearing force during the stirring may inactivate the enzyme. Especially for immobilized enzyme, the optimal method is to use an immobilized enzyme packed bed reactor, so that the production process of chloramphenicol succinate can be continuous, the inactivation of the enzyme can be reduced to the maximum extent, and the recycling rate can be improved.
According to the invention, in the step (2), a mixed solvent of a good solvent and a poor solvent in a certain proportion is used as a crystallization solvent for refining the chloramphenicol succinate, wherein the good solvent can be any one of methanol, ethanol and acetone or a mixed solvent thereof, and the poor solvent is water. In the examples, methanol/water is preferably mixed at a volume ratio of 1:1 as a crystallization solvent, and the amount of the mixed solvent added is 8 to 12 times, preferably 10 times, the mass of the chloramphenicol succinate solid to be purified and crystallized.
According to the crystallization process in the step (2), methanol is firstly added and stirred to dissolve the chloramphenicol succinate solid crude product at the temperature of 20-40 ℃, then purified water is slowly added, the temperature is slowly reduced to 0-5 ℃, and finally standing is carried out for 2-6 hours for crystallization.
In the examples, the dissolution temperature is preferably 30 ℃, the standing crystallization temperature is preferably 4 ℃, and the standing crystallization time is preferably 4 hours.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention.
The conversion in the examples was determined by high performance liquid chromatography: agilent 1200 liquid chromatograph, column: c182.1mm × 250mm, mobile phase: water/acetonitrile 85/15, flow rate 0.5mL/min, detection wavelength: 280nm, column temperature: and (4) room temperature. Conversion was product peak area/(residual chloramphenicol peak area + product peak area) × 100%.
The lipases used in the examples are shown in Table 1.
Table 1: lipase types and their sources.
(Code) | Enzyme | Source |
E01 | Lipozyme RMIM | Rhizomucor miehei |
E02 | Lipozyme TLIM | Thermomyces lanuginosa |
E03 | Novozyme 435 | Candida Antarctica |
E04 | Lipase PS | Pseudomonas cepacia |
E05 | Lipase AK | Pseudomonas fluorescens |
E06 | Lipase AYS | Candida rugosa |
E07 | Lipase AS | Aspergillus niger |
E08 | IMMOZYME CALA | Candida Antarctica |
Example 1
Enzyme screening assay: 0.32g (1mmol) of chloramphenicol, 0.11g (1.1mmol) of succinic anhydride, 0.065g of lipase, 5mL of acetonitrile, and the reaction was stirred at room temperature for 4 hours, the reaction equation is shown in FIG. 1, and the enzymes used and the corresponding conversions are shown in Table 2 below.
Table 2: the enzymes used and their conversion correspond to the table.
Lipase | E01 | E02 | E03 | E04 | E05 | E06 | E07 | E08 |
Conv.% | 52% | 38% | 74% | 25% | 0 | 5% | 12% | 45% |
Example 2
Solvent screening test: 32g (1mmol) of chloramphenicol, 0.11g (1.1mmol) of succinic anhydride, 0.065g of lipase E03, 5mL of acetone, and the reaction was stirred at room temperature for 4 hours, the reaction equation is shown in FIG. 2, and the solvents used and the corresponding conversions are shown in Table 3 below.
Table 3: the solvents used and the corresponding transformation tables.
Solvent | CH3CN | toluene | acetone | THF | dioxane | MeOtBu | iPr2O |
Conv.% | 74% | 15% | 80% | 51% | 32% | 60%% | 67%% |
Example 3
Anhydrous test: 0.32g (1mmol) of chloramphenicol, 0.11g (1.1mmol) of succinic anhydride, 0.065g of lipase E03, a drying agent (5% by mass of the solvent) and 5mL of acetone were stirred at room temperature for 4 hours, the reaction equation is shown in FIG. 3, and the drying agent used and the corresponding conversion are shown in Table 4 below.
Table 4: the desiccant used and the corresponding conversion table.
| Silica gel | 4A M.S. | Na2SO4 | MgSO4 | CuSO4 | Na2CO3 | |
Conv.% | 85% | 88% | 80% | 76% | 70% | 82%% |
Example 4
Temperature test: 0.32g (1mmol) of chloramphenicol, 0.11g (1.1mmol) of succinic anhydride, 0.065g of lipase E03, 4A molecular sieve (5% of the mass of the solvent) and 5mL of acetone were reacted for 4 hours with temperature-controlled stirring, the reaction equation is shown in FIG. 4, and the temperatures used and the corresponding conversions are shown in Table 5 below.
Table 5: the temperatures used and the corresponding conversion tables.
Temp. | 30℃ | 35℃ | 40℃ | 45℃ | 50℃ |
Conv.% | 88% | 90% | 93% | 94% | 85% |
Example 5
Enzyme addition test: 0.32g (1mmol) of chloramphenicol and 0.11g (1.1mmol) of succinic anhydride were added to the mixture, and the mixture was reacted at 40 ℃ for 8 hours by adding various amounts of lipase E03, 4A molecular sieve (5% by mass of the solvent) and 5mL of acetone, the reaction equation is shown in FIG. 5, and the amounts of the enzymes used and the corresponding conversions are shown in Table 6 below.
Table 6: the amount of enzyme used and the corresponding conversion table.
Example 6
Small test experiment: 3.23g (10mmol) of chloramphenicol, 1.1g (11mmol) of succinic anhydride, 0.48g of lipase E03, 15 particles of 4A molecular sieve and 50mL of acetone, stirring and reacting at 40 ℃ for 8h, filtering, adding 0.2g of activated carbon into the filtrate, heating and stirring for 10min, filtering, and removing the solvent from the filtrate under reduced pressure to obtain a white solid product. And (3) adding 5mL of methanol into the crude product at room temperature for dissolving, slowly adding 5mL of purified water while stirring, slowly cooling to 4 ℃, standing at a constant temperature for 6h, separating out white needle-shaped crystals, filtering, and drying the obtained crystals in vacuum at 50 ℃ for 2h to obtain 3.1g of chloramphenicol succinate pure product, wherein the yield is 73%, and the purity is more than 99%.
Example 7
The embodiment provides a process technology for synthesizing chloramphenicol succinate through enzyme catalysis, which comprises the following steps:
(1) the reaction process is as follows: 32.3g (100mmol) of chloramphenicol, 11g (110mmol) of succinic anhydride, 4.8g of lipase, 150 particles of 4A molecular sieve and 500mL of acetone are stirred and reacted for 12h at 40 ℃, the mixture is filtered, 2g of activated carbon is added into the filtrate, the mixture is heated and stirred for 10min for decolorization, the filtrate is filtered, and the solvent is removed from the filtrate under reduced pressure to obtain a white solid product.
(2) And (3) refining: and (3) adding 50mL of methanol into the crude product at room temperature for dissolving, slowly adding 50mL of purified water while stirring, slowly cooling to 4 ℃, standing at constant temperature for 8h, separating out white needle-shaped crystals, filtering, and drying the obtained crystals at 50 ℃ in vacuum for 2h to obtain 34.2g of the chloramphenicol succinate pure product, wherein the yield is 79%, and the purity is more than 99%.
The chromatographic analysis of chloramphenicol succinate prepared by the method of the present invention showed that the purity of the chloramphenicol succinate was high as shown in fig. 6, as can be seen from fig. 6.
It should be noted that the above-mentioned embodiments illustrate rather than limit the scope of the invention, which is defined by the appended claims. It will be apparent to those skilled in the art that certain insubstantial modifications and adaptations of the present invention can be made without departing from the spirit and scope of the invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011577379.4A CN112538506B (en) | 2020-12-28 | 2020-12-28 | A kind of process method of enzymatically synthesizing chloramphenicol succinate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011577379.4A CN112538506B (en) | 2020-12-28 | 2020-12-28 | A kind of process method of enzymatically synthesizing chloramphenicol succinate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112538506A true CN112538506A (en) | 2021-03-23 |
CN112538506B CN112538506B (en) | 2023-04-25 |
Family
ID=75017689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011577379.4A Active CN112538506B (en) | 2020-12-28 | 2020-12-28 | A kind of process method of enzymatically synthesizing chloramphenicol succinate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112538506B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102424829A (en) * | 2011-10-26 | 2012-04-25 | 苏州汉酶生物技术有限公司 | Method for synthesizing temsirolimus through enzyme catalysis |
CN103193667A (en) * | 2013-04-12 | 2013-07-10 | 张家港威胜生物医药有限公司 | Method for preparing chloramphenicol succinate |
CN110028420A (en) * | 2019-02-27 | 2019-07-19 | 郑州明泽医药科技有限公司 | A kind of synthetic method of chloromycetin sodium succinate |
-
2020
- 2020-12-28 CN CN202011577379.4A patent/CN112538506B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102424829A (en) * | 2011-10-26 | 2012-04-25 | 苏州汉酶生物技术有限公司 | Method for synthesizing temsirolimus through enzyme catalysis |
CN103193667A (en) * | 2013-04-12 | 2013-07-10 | 张家港威胜生物医药有限公司 | Method for preparing chloramphenicol succinate |
CN110028420A (en) * | 2019-02-27 | 2019-07-19 | 郑州明泽医药科技有限公司 | A kind of synthetic method of chloromycetin sodium succinate |
Non-Patent Citations (2)
Title |
---|
AYLA M.C. BIZERRA 等: "Enzymatic regioselective production of chloramphenicol esters", 《TETRAHEDRON 》 * |
FENGYING DONG等: "Transesterification Synthesis of Chloramphenicol Esters with the Lipase from Bacillus amyloliquefaciens", 《MOLECULES》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112538506B (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kurbanoglu et al. | Asymmetric reduction of substituted acetophenones using once immobilized Rhodotorula glutinis cells | |
CN113774094A (en) | A kind of enzymatic synthesis method of medium and long chain triglyceride | |
CN105754983A (en) | Immobilized enzyme for preparing Ezetimibe midbody and preparation method of immobilized enzyme | |
Cimporescu et al. | Efficient kinetic resolution of 1, 5-dihydroxy-1, 2, 3, 4-tetrahydronaphthalene catalyzed by immobilized Burkholderia cepacia lipase in batch and continuous-flow system | |
US10870869B2 (en) | Enzymatic method for preparing glyceryl butyrate | |
CN112538506A (en) | Process method for synthesizing chloramphenicol succinate through enzyme catalysis | |
CN105969836B (en) | A kind of method for enzymatic splitting of abacavir chiral intermediate Vincelactone | |
CN102120977B (en) | Microbacterium chocolatum and method for preparing (4S,5R)-half ester by using same | |
JP4880604B2 (en) | Preparation method of mycophenolate mofetil by enzymatic transesterification | |
CN101560527B (en) | Method for lipase-catalyzed synthesis of feruloylated acylglycerol in solvent-free system | |
D’Antona et al. | Synthesis of novel cyano-cyclitols and their stereoselective biotransformation catalyzed by Rhodococcus erythropolis A4 | |
CN102409068B (en) | Preparation method for (3aS, 6aR)-biotin chiral lactone | |
US11286511B2 (en) | Method for preparing troxerutin ester using whole-cell catalysis | |
WO2008143146A2 (en) | Method for producing glyceric acid | |
CN114634957B (en) | Method for synthesizing 4AA intermediate by biocatalysis | |
Tombo et al. | Preparation of Chiral 2, 4-Dimethylglutaric Acid Monoesters from the Racemic Diesters by means of Microbes and Microbial Esterases | |
JP2005117905A (en) | Process for producing optically active 1-benzyl-3-pyrrolidinol | |
CN102952760B (en) | A strain of Rhodococcus erythropolis capable of converting quinine into (S)-3-quinine alcohol and its transformation method | |
JP3893721B2 (en) | Method for producing optically active compound | |
JP4069742B2 (en) | Optical resolution of carboxylic acid esters by microorganisms | |
JP2006014636A (en) | Method for producing acyl derivative | |
JPS6261587A (en) | Production of optically active (r)-hydroxymandelic acid ester intermediate | |
CN112831529A (en) | Preparation method of chiral 3-hydroxyvaleric acid and salts/esters thereof | |
JP3007461B2 (en) | Method for producing optically active 2-cyclohexenylacetic acid and its ester | |
CN114231571A (en) | Production method for catalytic synthesis of monoglyceride stearate by immobilized composite lipase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |